CL2022000786A1 - Metodos de tratamiento para modificar la hemodinamica - Google Patents

Metodos de tratamiento para modificar la hemodinamica

Info

Publication number
CL2022000786A1
CL2022000786A1 CL2022000786A CL2022000786A CL2022000786A1 CL 2022000786 A1 CL2022000786 A1 CL 2022000786A1 CL 2022000786 A CL2022000786 A CL 2022000786A CL 2022000786 A CL2022000786 A CL 2022000786A CL 2022000786 A1 CL2022000786 A1 CL 2022000786A1
Authority
CL
Chile
Prior art keywords
human subject
hemodynamics
modify
treatment methods
treatment
Prior art date
Application number
CL2022000786A
Other languages
English (en)
Inventor
Gert Wensvoort
Roelof Peter Pickkers
Original Assignee
Ebi Anti Sepsis B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ebi Anti Sepsis B V filed Critical Ebi Anti Sepsis B V
Publication of CL2022000786A1 publication Critical patent/CL2022000786A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona un método de tratamiento que comprende la administración de un péptido AQGV, o un análogo funcional del mismo, a un sujeto humano, donde el sujeto humano opcionalmente tiene una función renal deteriorada, en donde el tratamiento para administrar un péptido AQGV comprende mantener o mejorar la estabilidad hemodinámica en el sujeto humano, como un sujeto humano que padece o se considera que padece la enfermedad de Clarkson (CLS).
CL2022000786A 2019-09-30 2022-03-29 Metodos de tratamiento para modificar la hemodinamica CL2022000786A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962908442P 2019-09-30 2019-09-30
US202063045752P 2020-06-29 2020-06-29

Publications (1)

Publication Number Publication Date
CL2022000786A1 true CL2022000786A1 (es) 2022-11-04

Family

ID=72811922

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000786A CL2022000786A1 (es) 2019-09-30 2022-03-29 Metodos de tratamiento para modificar la hemodinamica

Country Status (10)

Country Link
US (1) US20220370543A1 (es)
EP (1) EP4037701A1 (es)
JP (1) JP2023503790A (es)
KR (1) KR20220106114A (es)
AU (1) AU2020360113A1 (es)
CA (1) CA3152346A1 (es)
CL (1) CL2022000786A1 (es)
CO (1) CO2022005113A2 (es)
MX (1) MX2022003820A (es)
WO (1) WO2021066649A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521744A (ja) * 2020-04-06 2023-05-25 バイオテンプト ビー．ブイ． 感染症における血行動態を変更する為の方法及び手段
EP4221737A1 (en) * 2020-09-30 2023-08-09 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
AU2022359382A1 (en) * 2021-10-05 2024-05-02 Biotempt B.V. Angiogenic control, preferably combined with glycaemic control.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1466612A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Treatment of inflammation and sepsis with hCG derived peptides
PL2120991T3 (pl) * 2007-02-12 2014-07-31 Biotempt Bv Leczenie urazów krwotocznych krótkimi oligopeptydami
WO2009014440A1 (en) * 2007-07-23 2009-01-29 Biotempt B.V. Inhibition of renal ischemia reperfusion injury by synthetic oligopeptides

Also Published As

Publication number Publication date
CA3152346A1 (en) 2021-04-08
WO2021066649A1 (en) 2021-04-08
EP4037701A1 (en) 2022-08-10
CO2022005113A2 (es) 2022-06-21
MX2022003820A (es) 2022-09-19
KR20220106114A (ko) 2022-07-28
US20220370543A1 (en) 2022-11-24
AU2020360113A1 (en) 2022-04-14
JP2023503790A (ja) 2023-02-01

Similar Documents

Publication Publication Date Title
CL2022000786A1 (es) Metodos de tratamiento para modificar la hemodinamica
CL2019003496A1 (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MD3532486T2 (ro) Compuși de tirozină-tirozină peptidică ciclică cuplaţi la anticorp ca modulatori de receptori Y ai neuropeptidei
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
CY1116938T1 (el) Αναπληρωτικη θεραπεια της ασθενειας huntington και αλλων ασθενειων πολυγλουταμiνης
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
CO2020000260A2 (es) Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202090705A1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
AR117861A1 (es) Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA201500765A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов